This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Viking Therapeutics, Inc. (VKTX) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $29.28, indicating a +1.14% shift from the previous trading day.
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $29.73, denoting a +0.61% change from the preceding trading day.
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
by Zacks Equity Research
With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the market.
Sage Therapeutics (SAGE) Up 7.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Sage Therapeutics (SAGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma
by Sundeep Ganoria
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply
by Zacks Equity Research
The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its obesity drug VK2735.
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?
by Kinjel Shah
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $29.10, indicating a +1.46% shift from the previous trading day.
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
by Ahan Chakraborty
Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug
by Zacks Equity Research
Per the terms of the deal, AbbVie will lead the development and commercialization of the obesity drug developed by Gubra.
Viking Therapeutics, Inc. (VKTX) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $28.87, denoting a +0.7% change from the preceding trading day.
Perrigo Gears Up to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
PRGO's fourth-quarter top line is likely to have benefited from higher net price realization for its products through strategic price increases.
Should You Buy VKTX Stock Amid Renewed M&A Speculations?
by Sundeep Ganoria
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics, regardless of buyout speculations.
What's in the Cards for Viatris Stock This Q4 Earnings?
by Zacks Equity Research
VTRS' Q4 results are likely to gain from new product launches in all major geographies.
ADMA Biologics Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On ADMA's fourth-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
BioMarin to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
When BMRN reports fourth-quarter earnings, investors will likely focus on the sales performance of its dwarfism drug Voxzogo.
LLY Rises More Than 4% in a Week: How to Play the Stock
by Kinjel Shah
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%
by Zacks Equity Research
Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.
Eli Lilly Stock Before Q4 Earnings: To Buy or Not to Buy?
by Kinjel Shah
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $33.69, moving +0.78% from the previous trading session.
Viking Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
Since VKTX is devoid of marketed drugs, investors will focus on pipeline updates when it reports Q4 results next week.
How to Play NVO Stock After New Drug's Success in Obesity Study
by Ahan Chakraborty
The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh in on the stock's growth prospects.